Officials give update on Operation Warp Speed and coronavirus vaccines
Officials with the U.S. Department of Health and Human Services and the Department of Defense provide an update on Operation Warp Speed and the status of COVID-19 vaccine distribution.
a gritty of our distribution system, which is now successfully delivered to over 14,000 locations, essentially without a hitch. Over the last several days, we've averaged around 700,000 reported vaccinations each day, and we are on track to hit one million per day in a week to 10 days time. In total, we have more than nine million first vaccinations already given farm or than any Western country. By the end of next week, 95% of long term care facilities will have had their first visit with vaccine doses. All of this means it's time to move on to the next phase of the vaccination campaign, as we had planned to dio when the data showed we could. This next phase reflects the urgency of the situation we face. Every vaccine dose that is sitting in a warehouse rather than going into an armed could mean one MAWR life lost or won Mawr hospital bed occupied The next phase has several components. First, we're expanding. The group's getting vaccinated because state restrictions on eligibility have obstructed speed and accessibility of administration. Second, we're telling states to expand the channels and access points for administering vaccines and we're helping them to do so. Third, we are releasing the entire supply we have for order by states rather than holding second doses in physical reserve. Fourth, we're announcing a forthcoming change to how we allocate doses in order to encourage states to support rapid vaccination and to focus on the most vulnerable. So the first point about expanded eligibility? We're telling states today that they should open vaccinations to all of their most vulnerable people. That is the most effective way to save lives now. And some states heavy handed micromanagement of this process has stood in the way of vaccines, reaching a broader swath of the vulnerable population more quickly. Specifically, as Dr Redfield will discuss, we're telling states they should open vaccinations to all people over age 60 65 over, and all people under age 65 with a co morbidity with some form of medical documentation as defined by governors, leaders in some states have forged ahead with steps like this in very diverse settings and demonstrated riel success. I'll just mention a couple like Governor Lamont in Connecticut and Governor Justice in West Virginia, expanding eligibility to all of the vulnerable is the fastest way to protect the vulnerable. It's simply much easier to manage allocating vaccines and appointments to everyone 65 over, rather than narrower, more complex categories, and it enables states to use much more diverse administration channels. There was never a reason that states needed to complete vaccinating all health care providers before opening vaccinations to older Americans and other vulnerable populations. States should not be waiting to complete one a priorities before proceeding to broader categories of eligibility. Think of it like boarding an airplane. You might have a sequential order in which you bored people, but you don't wait until literally every person from a group has boarded before moving on to the next. You have to keep the process moving. Imagine if you find a gate agents for boarding people out of order. You'd be standing at the gate for hours. Of course, moving on from initial phase of, say, healthcare workers before everyone is vaccinated is not declaring victory for that category. States should continue working to support vaccinations of those populations, but moving on to broader populations when supply meets. Demand was always part of the recommendations CDC had provided to States. Second, we're telling states toe, open up more channels for administration and we're helping them do so. Hospital hospitals made sense as the early distribution sites when the focus was on health care workers. But they're not where most Americans go To get vaccines, states should move on to pharmacies, community health centers and mass vaccination sites as desired or needed to support that work. Last week, we announced that states could start using pharmacies enrolled through our federal partnership with 19 pharmacy chains and associations. General Purna Dr Redfield in some pharmacy leaders held a briefing for governors on this topic last Thursday. This federal partnership allows states to allocate vaccines directly to these partners, and these partners connect administer vaccines to particular groups and eventually to the general public. These pharmacy partners handle the administrative tasks such as scheduling appointments and reporting vaccinations. States can and should choose the most strategically placed pharmacy partners to send vaccines to now. We're also activating are federally qualified community health centers for vaccination. Some of these community health centers are already being utilized by state plans, but every state should be using them. Community health centers have mawr than 13,000 delivery sites across America, and they have both, particularly convenient locations and strong connections in low income and minority communities. Further, if states wish to set up mass vaccination sites, we stand ready to help both through 500 guidance and other support, including deploying personnel to assist with technical expertise and set up. We're here to work with them. States have ample funding, including $3 billion MAWR, on the way to support such efforts. Third, we're now making the full reserve of doses we have available for order. We are 100% committed to ensuring a second dose is available for every American who receives the first dose. Let me repeat that our approach continues to ensure that there will be a second dose available for someone who gets a first dose of vaccine based on the science and evidence we have. It is imperative that people receive their second doses on time. That's what the science says, and ignoring that would be reckless. But we had always planned to move to um, or advanced phase of how we manage this. Once we had confidence in our supply chains. That is the key trigger we needed to see because we now have a consistent pace of production, we can now ship all of the doses that had been held in physical reserve, with second doses being supplied by doses coming off of manufacturing lines with quality control going forward each week. Doses available would be released to first cover the needed second doses and then cover additional first vaccinations. Finally effective two weeks from now, we're changing how we allocate first doses among the states. In order to ensure doses are being put to use and put to use for the most vulnerable. We will be allocating them based on the pace of administration, as reported by states and by the size of the 65 over population in each state. We're giving states two weeks notice of this shift to give them the time necessary to plan and to improve their reporting if they think their data is faulty. This new system gives states a strong incentive to ensure that all vaccinations are being promptly reported, which they're currently not, and it gives states a strong incentive to ensure doses air going toe work, thio going toe work, protecting people rather than sitting on shelves or in freezers. With the case counts we face now, there is absolutely no time to waste. We need doses going toe where they'll be administered quickly and where they'll protect the most vulnerable. Finally, as we face rising case counts in a number of parts of the country. We need all Americans to keep up the same public health measures we've been recommending throughout this crisis. Hope is here in the form of vaccines. We just have to keep up our guard for a bit longer. I want to add one more key message to our recommendations of washing our hands, watching your distance and wearing your face coverings when you can't watch your distance. If you test positive and or at risk for severe disease, meaning you are over 65 or have a co morbidity, you should be asking your doctor or health care provider why you are not being given one of the FDA authorized antibody therapies that air in ready supply. We have products sitting on the shelves that can help keep people out of the hospital. That is just a zoo. Unacceptable is vaccines sitting on shelves, unused people in the appropriate categories should be asking their doctors or healthcare providers why they aren't being offered these antibody therapies. With that, I'll hand things over toe. Dr. Redfield are 100 Director Dr Redfield. Thank you, Mr Secretary. I want to echo some of the important comments that the secretary made, um, clearly, as we began vaccination with our frontline healthcare workers and individuals and long term nursing care and assisted living, that was the initial phase to begin to roll out of this vaccine distribution, as the secretary said. And as we sit here in the fourth week of this vaccination program, we now at a time where actually there's more vaccine available, then is being requested for vaccination within the one a group through the pipe 100 guidelines that came out on vaccination to the States were never meant to be somehow finished the first phase. Then you move to the second phase, Then you move to the third. So I'm here is the 500 director Thio. Ask our governors, echo what the secretary said and strongly recommend the vaccination now be expanded to those individuals 65 or over and those individuals between 16 or 18, depending on the vaccine being used to 64 that have a co morbidity. With the medical documentation off such we clearly have enough vaccine at this point to begin to expand and get Maura Maura of the vulnerable individuals in our country vaccinated. This is particularly important right now as we're seeing the post holiday surge surge. We have many jurisdictions now that are on the verge of going from a linear growth thio basically exponential growth. And we believe it's critically important at this time to get those most vulnerable people as quickly as we can into vaccination programs as a key strategy to maintain hospital resilience. I also want to echo what the secretary said about the importance of using the approved E Way approved monoclonal antibodies for individuals at highest risk that developed symptoms prior to hospitalization. That's a second really important, um, intervention that we have at this moment to maintain hospital resilience. And finally, I just have to echo also the closing comments of the secretary. This is a time that we call on all Americans to be vigilant in the mitigation steps that we have asked, particularly in their own health households, most of transmission that is occurring in our nation right now. It's not occurring in the public square. It's occurring. One household, the one household, the one household. So again wear mask. They work social distance. It works of staying away and being smart about crowds washing your hands. They work. We need to work altogether. Now it's going to be a difficult, difficult January and probably February. But with the vaccine and the new Therapeutics we have, there's really strong light at that end of that tunnel as we enter March. But we need Thio really commit right now and get us many Americans vaccinated as we can. That air particularly the most vulnerable in at risk for hospitalization. Thank you, general. Permanent. Oh, God! Stuff is good. Yeah, General Permanent. We'll talk next. Good morning, everybody. So we are in the beginning of our continuing our new for our execution, right? And I'm very excited. I'm very proud about it. Ah, month ago is when we started delivering vaccines around the world around the country on they went to the hospitals. Aziz, we focused on the categories for first line medical responders. Four weeks later, we've made significant progress as the Secretary has highlighted on there is nobody working harder right to ensure that vaccines are being distributed than the O. W s team in execution to get it to where it needs to be. So distribution of the vaccines is getting them to the States so that they can, uh, ensure that it gets to the arms. And we are enabling that every day. We, as a secretary said, have sent over 25 million doses of vaccines over to 16,000 different locations. Really, really great effort. The cadence of allocations, the cadence of orders, the cadence of picking and packing, the cadence of what's being shipped is really become a remarkable feat for all of us, right? The whole of America to be proud off. We are executing this every day, every week, and the months will go by on the result. The effects will be safe and effective vaccine to the American people. I do want to, as I always do, thank the men and women of Pfizer, Moderna, McKesson, FedEx and UPS who are working uh, 24 hours a day, seven days a week to deliver the vaccine in a timely manner. A za secretary talked about our responsibility is to make sure all vaccine that is releasable available for distribution gets out to the American people. And that is what we're doing as early as 24 November. Standing right here talking to you. I talked about our ability to plan our ability to collaborate, our ability to see ourselves and then to make sure we continue to execute, to the maximum extent possible, delivering the most vaccines to the American people. That is what we're doing now. That is what the secretary laid out in execution of how we're managing the second dose is to ensure first and foremost, it's always available. But second, we ensure that the max available doses of vaccine are available to the American people every day. Are my personal confidence, uh, in both the distribution capability? As demonstrated over the last four weeks, Azaz and the addition of manufacturing confidence has increased significantly, which allows me to approach and execute distribution and allocation of the vaccines differently. It ensures maximum execution and allows us to pass maximum doses of vaccine to the American people in a timely manner. Today I want to give you a quick update of where we are with the facilities, uh, that we've made significant progress in working to get long term health care facilities up and running in collaboration with CVS and Walgreens. We know we have 70,000 facilities that are enrolled, which includes skilled nursing facilities and assisted living facilities. We started in week one, right three weeks ago, with 900 facilities in three weeks. Since we've completed over 11,000 facilities, just under a million first doses have been given. 12,000 MAWR clinics are scheduled this week and every week following. As we go forward today, we know that we are making a difference in these facilities, and it is because of the great work by the CDC, CVS and Walgreens that are making a difference, as the secretary said were quickly coming on to administering first dose toe. Everybody in these in this category we are expanding our distribution to the retail pharmacies as a secretary talked about, we have opened it up for states to utilize the over 40,000 provider pharmacy providers that are enrolled and we want to expand it up to 70,000 providers that are enrolled. We think that we can open up the aperture and give access greater access to the American people through the pharmacies. What does it do? It allows us to have confidence in the execute er's. It allows us to distribute it throughout the country. It allows us to give a place where the American people are comfortable of going and receiving the shot. I want to give you four, uh, slides that I asked the team to put together. The first slide is the vaccinations that we executed on day one of distribution of the fights or product, right? We went to over 636 sites on day one across the country of our country. Why do we do this specifically, it was the Pfizer vaccine. We knew there was cold chain requirements. We wanted to ensure capability and capacity, match the distribution. We worked with states. We collaborated with them, and we put it exactly where they wanted it when they wanted it. On the second week, when we brought the modern a vaccine in, we were able to expand distribution primarily because of the availability of doses at lower amounts where the modern a vaccine is at 100 minimum ordering at 100 doses. So what could we do? We could expand out through the country because of the dose requirement, minimum dose requirement and also less refrigeration requirement. We were able to send doses to long term health care facilities. We were able to extend it into doctor's offices and into pharmacies, as the state's asked us to do so. The expansion was quick and rapid in just a week. Now today, as of yesterday, we have gone to over 16,000 locations across the country, right as depicted on this slide, we go there on a routine basis, delivering vaccines as directed by the states in distribution to the quantities and locations that they want, really covering the mass population of the country. Now what is in the realm of possible this last slide as we open up the 70,000 pharmacy chain and individual capabilities we are covering the entire United States and vaccine can be distributed as of this week to where the states would like it to go across the country. We know that these pharmacies, because we've been working with them at the C. D. C level, are ready to execute this mission and as the states allocate vaccine to them and direct it. We are ready to deliver toe all these locations every day. So in closing, uh, challenging times, as I've told you many times on, the secretary said we were not fighting the plan, right? We're fighting the situation, and we're making adjustments on moving forward in that light. Just professionals on their supported staff are really just doing a tremendous job on. I just want to say thanks to all of you. So that concludes my comments, Mr Secretary. Thank you very much. And I did want to note, as you saw, Dr Slough is with us on stage and will be available for questions. He just didn't feel the need to have an opening opening statement. But Michael Prep Thank you all. We will now open up for questions, Operator. A friendly reminder that when asking a question, please state your name and publication and please keep your questions short as possible so we can get to a zoo, many as we can that we have. Thank you so much. If you would like to ask a question, please Press star, then one on your phone. And be sure to provide your name and media outlets. Our first now is from Drew Armstrong with Bloomberg News. So your line is open. Hi. It's true I run our vaccine tracker here and had a question for you all about what has actually been the problem in administering shots in some of these states that are showing low numbers of percentage of the distributions to them used because clearly there's a number of states they're working through between 70 and 80% of their distributions on a rolling basis. But others in Mississippi, Alabama, Georgia, North Carolina, perpetually kind of stuck in a very low percentage of what's been shipped to them is that it got distributed to the wrong places. Are they having problems with our their holdups in shipping what is actually going on here? Because I don't think we've really gotten a good answer from anybody about where these bottlenecks are there, preventing some states from reaching some of the numbers that you all excited as being successes elsewhere, Drew and our last general permit, or Dr Redfield to add, add to what I've got to say. But first we need to recognize that we're now four weeks into this program, and this is a major operational logistics issue. It's a scale up. As with any enterprise, you're going to have a scale up that is predictable and known that that would happen. But we have seen variable performance among the states and among providers. What's going on there now? Each state maybe slightly different. But for the most part, what we have seen is the states that are lagging. It certainly could be a data issue. The health commissioner here in the District of Columbia, for instance, revealed that 40% of pharmacies aren't reporting. We had data reporting issues with one chain pharmacy in terms, its ability to connect into the system on vaccinations. We had one state that has had some significant challenge with interconnectivity of data reporting systems. And a Dr Redfield can let you know what we're asking for is very novel In the history of vaccination programs in the United States, usually with public health vaccinations are providers have to report within 30 days, right, Bob within 30 days. Now they've they've signed as part of their agreement to be providers in Tiberias with Operation Warp speed agreements to provide their data within 72 hours. But that's a major workflow change for them. And they're going to be kinks in the system on that data, improving consistently over time. And I think with the new incentives that we're announcing today, that states will receive their allocations in part based on the data that we have on what percent of vaccines they've received. Have they actually gotten administered? We'll see that data improved. The other major barrier and I talked about this last week has been states that are being overly prescriptive and trying to micromanage every single dose of vaccine down toe. Who gets it to ensure that only Group one A people get vaccinated before they're willing to open up and look a Group one be people, even if that's the approach that they're taking. So that might be states that are insisting that all health care providers have to vaccinated before you start vaccinating the most vulnerable. That's why, from the get go, I've talked about the need toe, not be cab and in by the different groups from the A, C. I P or from the C. D. C. They're not meant to be prescriptive. Some governors have overreacted, have taken them in overly prescriptive manner. And this is a logistical issue. This is operational, You focused. You let the perfect be the enemy of the good in the mass vaccine campaign like this, I said last week, we would rather have some low lower priority individuals get vaccinated along with the high priority individuals if it makes us go fast. And if it avoids vaccine sitting on the shelves. And for the love of God, not having vaccine actually wasted or thrown away because of a failure to administer. Um, so those have been the major issues, really, At the state level, it's first reporting, overly prescriptive, approaches the vaccination and unwell. And then finally, an unwillingness toe move toe alternative channels of distribution overall, um, very effective partners in these vaccine programs as they have networks. They have primary care practices there themselves health systems, not just hospitals. And so if they can get to their patients, get to their customers and clients that air vulnerable those 65 above and those under age 60 64 below who have co morbidity ease Well, that's ideal also, but use every channel, get the vaccine out there I would rather have people, um, have people, uh, working to get appointments to get vaccinated, then having vaccine going toe waste, sitting in freezers, general partner or Dr Redfield. Anything you'd like to add, right. Thank you, Mr Secretary. And I agree with your answers. Uh, the other thing I would just say is right now, C d. C. Is doing a I'll call it Deep dive on the 64 jurisdictions to try to understand exactly what that issue is. I do think a lot of it is reporting. As the Secretary said, the standard that CDC has had in the past for reporting vaccination was to providers to report within 30 days. We're now asking them to report within three days. So I do think some of that is part of the hiccup. But we're doing a deep dive in all the jurisdictions, as was mentioned. Some of them are less than 15%. And then we have other jurisdictions that are over 80%. To understand exactly what those factors are pretty confident, we'll have an understanding that by the end of the week did you mhm secretary, I agree with all that was just said completely. I would just add the separation of distribution from actual administration were 9%. Eso, in other words, is long. If the state tells us where they want it in one of the 70,000 enrolled providers we are able to distribute there in accordance with the order on we, we Pfizer, Madonna, McKesson, UPS and FedEx are literally going through snowstorms on distributing vaccine every day, Uh, to the to the location as desired at a very high success rate. Next question, that is, from Dan Varga. No, With buzzfeed news, your line is open. Thank you, Dan, for Ghana Buzzfeed news. I'm wondering if this change will necessitate any widening of the time window for the 21 day and 28 day second dose. What? What is the widening? How close to 21 or 28 days you have to get now. Uh, wh Ose Advisory committee has said you might go to six weeks. Um what do you see as the window for that? Or what? Do you recommend eso Dan, Thank you for asking about that. I want to be very clear. The labeled indication from the FDA on the vaccines for the Pfizer vaccine is 21 days between first dose and second dose in 28 days between first dose and second dose for the moderate vaccine. That's what the clinical trials were based on. That is the data submitted to the FDA, and that is what we're executing towards. So that is the goal. Now, if people end up coming in a day or so on each side Uh huh. And evidence that has been generated to support these incredibly safe and effective vaccines. And I think that's part of why the American public has seen has shown such surging vaccine confidence that every aspect of this has been data and science driven. And the FDA will make the determinations of what a purpose administrations are the general laid out. And this was always part of the plan. Go back to my state number of these press conferences where I said, What we're going to do is manage the flow of vaccines. We must ensure that if you get a first vaccine, there will be a second vaccine at the 21 day or the 28 day market. The provider for you to get that we have two sources for vaccine, one would be holding back some of the initial stocks of vaccine that were that were, releasable in December to guarantee that we have that second dose. But I said over time, as we gain confidence in the manufacturing quality and processes of modern and Pfizer and with our deep, deep, deep operation, warp speed engagement Madonna and are increasing engagement now with Pfizer in their manufacturing processes and use of the Defense Production Act, we have greater visibility and greater confidence in their production capabilities. We now have been able to move to where we do not need to hold back reserve doses because we can predict with better certainty the doses that will arrive off the production lines and quality control at the 21 day and 28 day mark to fulfill our second dose obligations to patients. And that will be our primary. And so if there heaven forbid or any type of glitches and production, the way this would work is new production off the production lines would be going towards first and foremost fulfilling the second dose obligation, and any first doses would be delayed to ensure that patients get at the 21 or 28 day mark that second dose. Thank you. We have time for two more questions. Thank you. Our next from Ricardo Alonso Zaldivar with Associated Press. Your line is now open. Hi. Thank you for taking my question. And, Mr Secretary, can you walk us through the change in allocation to the states that you announced today? Does that mean that some states may end up getting less than they otherwise would have? And is there a risk of disruption with that? And finally, um, do you have buy in to that approach from the incoming administration? So, Ricardo, thank you for the question on that. Uh so the two changes that we have outlined our first that are allocations among the states will not remain purely on a per capita basis, but rather be based on the reported data showing the percentages vaccine administered versus their allocations that they've received. In other words, if you're not using vaccine that you have the right to, then we should be re balancing two states that are using that vaccine. It is common sense. It seems hard to actually defy that. But we want to give notice, especially because of these data issues, we want to give notice within two weeks. We'll be doing that. So get your data in order. Work on that data. Ricardo, You may remember we followed a very similar approach when we were in shortage situations with from D severe doing allocations to the states on needing to get reported data on Romney, severe location and utilization on DSO We follow that approach and it worked exceptionally well in the context of room disappear on then thea other changes to really emphasize to make it very clear how vitally important it is to prioritize and focus on those who are most vulnerable for whom the vaccine will have the biggest effect in those of those aged 65 over. And those 64 below with co morbidity is and so that will be a change. I believe it's about 10 states most impacted based on the data. Uh, there would be fairly common sense where that would be. But again, our states aren't using 100% of their allocated vaccine. Eso This ends up being, I think, a t least in the interim of redistribution between and among the states that should not necessarily hurt many states, but will enhance the benefit to those that are actually getting vaccines done and perform. Thanks. Next question, please. Time for one last question. Our final question is from Tom Howell with The Washington Times, and your line is now open. Hi. Thanks for doing the call. Um, can you address the back end of a car? Does question about whether the Biden team has bought into that plan. And also conductor slowly update us on AstraZeneca and J and J well, and how much word made the determination on the changes and read in distribution allocation methodologies among the states. While we will certainly brief the Biden team on those changes we operate is, you know, with one government at a time. And we This is the approach that we believe best fulfills the mission and the current situation that we're facing. Thank you Ducks life. Thank you for your question. Uh, eso regarding the young sons vaccine. As you know, the face retrial is fully recruited. There are unfortunately fortunately for the trial. Very significant number of cases accruing we are very clear. We meaning operation and Johnson's pharmaceuticals. That analysis will be completed before the end of the month and the U A submission will take place at the end of this month. In terms of vaccine, those availability if submission is happening at the end of January 1 could project that approval of the emergency use authorization may happen somewhere in the middle of the month of February. We project to have single digit million number of those is available in the second half of February. We're trying to make that number get as close to a double digit number as possible and then a larger number in March and a much larger number in April. Remember, this is a one shot vaccine, so those are millions of individuals fully immunized in terms of the AstraZeneca vaccine. The assumption we are working on is that the emergency use authorization will be submitted on the basis of the ongoing Phase three trial in the US The face retrial is effectively fully enrolled. There are few individuals more enrolled on a primarily toe ensure appropriate representation of all diverse population in the country. Cases are accruing the 60 days upon completion off full immunization schedule, follow up safety as required by the FDA guidance happens during the first week of the month of March, and the projection would be to have a submission of the around that time assuming, of course, that cases have accrued again. Unfortunately, I think that will be the case on board. Hopefully, the vaccine again is efficacious, as has been shown in the trials conducted in Brazil and in the UK eso maybe an approval somewhere towards the larger part of the month of March, and a significant number of those is available around that time. And since you asked the question, maybe also update on the Novavax vaccine. The Novavax vaccine is the fifth program out of that is in face retrial or completed The face retrial The face of Israel has now recruited about 8000 or so subjects is recruiting very fast at a rate of 800 subjects per day. Volunteers. Hopefully we can go to a higher number. It's very important that people continue to participate generously Thio be volunteers in this clinical trial. The projection is to complete recruitment of this trial somewhere very early in the month of February on based on timelines of immunization, etcetera. Maybe there we can have an outcome somewhere in the month off very late March or in April. The Sanofi Trial program, which program we'll start face to be trial in the middle of February in a comparative trial to a messenger RNA vaccine. Maybe also on a progress. Part of things we are working now experimentally testing Sierra for identification, off immune correlates of protection. That's really super important because if and when we have the data somewhere in the middle of February is the projection currently that identifying immune cards of protection that will dramatically accelerate potential approval of other vaccines, including the protein vaccines, particularly that from Sanofi and vaccines from others and, of course, across the world, provided people use uh, read outs that are validated or cross validated with the read outs that have being used. I don't want to say a final final point is we are running a clinical trial. Phase three trial in adolescents 12 to 18 years of all of age with the modern A vaccine. Uh, it's a real challenge. It's being folks ongoing with try. Remember, I just said earlier. The Astros and the sorry Novavax vaccine is recruiting 800 subjects per day here. We're talking about 800 subjects in a month. It's really very important for all of us. For all the population in America, too. Realize that we can't have that indication unless adolescents aged 12 to 18 decide to participate. Of course, as a voluntary decision into the clinical trials, we need to recruit about 3000 subjects into the trial to complete them. Thank you. So this is very likely the last Operation warp speed briefing with this team for you all. I just wanted Thio Express three notes of thanks. First, I want to thank the members of the media who participated in these operation warp speed calls. You have been unfailingly professional and allowed a on educational and technical level briefing that I hope your readers and listeners and viewers have appreciated. We have tried it every step of the way to be factual and transparent with you and bring you on the journey with us of vaccine approvals and distribution and now administration. So thank you for making that possible. Second, I want to express my appreciation to Secretary former Secretary Esper, acting Secretary Miller and Deputy Secretary Norquist of the Defense Department the collaboration between D. O. D. And HHS has been unprecedented on Really in my, uh, in my decades around government government service. I've just never seen this type of collaboration and cooperation that's really that comes from the top. That is a credit to the leadership of the Defense Department to make this happen. So thank you for that. Finally, people is policy, and we, fortunately at the outset of Operation Warp Speed, were ableto have some exceptional people leading this in all of my time, leading in business and in government. I have never been part of a team that has that has that has a demonstrated teamwork and professionalism and integrity, discipline, as this team does. And I want to express my personal appreciation toe all of the members of the team, but especially General Purna, who was a hero for America before he did this. Now he's a hero for America's public health. Two months, chefs Lowey, who was a hero of the bio pharmaceutical industry before doing this and is now a hero of America's public health. These selfless individuals have dedicated every waking minute since they were tapped back in May toe lead. These efforts. The results have been remarkable. Andi. I hope that the next team with the Biden administration will be able to carry forward these results. We will do everything in our power to ensure a smooth and effective continued transition. The first meeting, I believe, of any transition team between this administration. The bite administration was before Thanksgiving. It was for Operation Warp speed. And we'll continue those efforts up through the last day of this administration into the body and into the Biden administration. So thank you all very much. We appreciate everything. Thank you, Mr Secretary. Uh, additional follow up questions can be sent to media at HHS dot gov and I'll turn it over to the operator to finish up the call. Thank you. Conference is now concluded again. Thank you, everyone, for your participation, Please go ahead and disconnect. Thank you very much. Mhm. Yeah.